IBRX icon

ImmunityBio

63 hedge funds and large institutions have $56.1M invested in ImmunityBio in 2017 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 23 increasing their positions, 14 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

more first-time investments, than exits

New positions opened: | Existing positions closed:

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

more funds holding

Funds holding:

more funds holding in top 10

Funds holding in top 10:

3.41% less ownership

Funds ownership: 19.11%15.71% (-3.4%)

33% less capital invested

Capital invested by funds: $83.2M → $56.1M (-$27.1M)

95% less call options, than puts

Call options by funds: $4K | Put options by funds: $80K

Holders
63
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$4K
Puts
$80K
Net Calls
Net Calls Change

Top Buyers

1 +$1.09M
2 +$364K
3 +$338K
4
Morgan Stanley
Morgan Stanley
New York
+$209K
5
Renaissance Technologies
Renaissance Technologies
New York
+$197K

Top Sellers

1 -$11.6M
2 -$1.63M
3 -$561K
4
BlackRock
BlackRock
New York
-$399K
5
SG Americas Securities
SG Americas Securities
New York
-$270K
Name Holding Trade Value Shares
Change
Change in
Stake
1
$12.2M
2
$11.9M
3
$8.26M
4
$5.7M
5
$3.63M
6
$1.65M
7
$1.41M
8
$1.28M
9
$1.18M
10
$1.05M
11
$1.01M
12
$544K
13
$515K
14
$488K
15
$395K
16
$364K
17
$356K
18
$348K
19
$304K
20
$273K
21
$251K
22
$247K
23
$214K
24
$212K
25
$207K